Retirement Systems of Alabama Has $38.96 Million Position in Exelixis, Inc. $EXEL

Retirement Systems of Alabama cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 0.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 883,994 shares of the biotechnology company’s stock after selling 7,337 shares during the quarter. Retirement Systems of Alabama owned about 0.33% of Exelixis worth $38,962,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EXEL. Assetmark Inc. raised its holdings in shares of Exelixis by 16.8% during the 2nd quarter. Assetmark Inc. now owns 240,158 shares of the biotechnology company’s stock valued at $10,585,000 after purchasing an additional 34,466 shares in the last quarter. Hantz Financial Services Inc. increased its position in Exelixis by 940.4% during the second quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after buying an additional 1,025 shares during the last quarter. Buck Wealth Strategies LLC raised its holdings in Exelixis by 70.9% during the second quarter. Buck Wealth Strategies LLC now owns 11,964 shares of the biotechnology company’s stock valued at $527,000 after buying an additional 4,964 shares in the last quarter. Flagship Harbor Advisors LLC raised its holdings in Exelixis by 13.5% during the second quarter. Flagship Harbor Advisors LLC now owns 7,156 shares of the biotechnology company’s stock valued at $315,000 after buying an additional 853 shares in the last quarter. Finally, Motley Fool Asset Management LLC lifted its position in shares of Exelixis by 11.0% in the second quarter. Motley Fool Asset Management LLC now owns 8,600 shares of the biotechnology company’s stock worth $379,000 after buying an additional 855 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Price Performance

NASDAQ:EXEL opened at $38.94 on Friday. Exelixis, Inc. has a one year low of $31.90 and a one year high of $49.62. The company has a fifty day moving average price of $38.81 and a 200 day moving average price of $40.21. The stock has a market cap of $10.48 billion, a P/E ratio of 18.72, a PEG ratio of 0.79 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the previous year, the firm posted $0.84 EPS. The business’s revenue was down 10.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on EXEL shares. UBS Group set a $38.00 price objective on Exelixis and gave the company a “neutral” rating in a report on Wednesday, July 30th. Morgan Stanley lowered their price target on Exelixis from $50.00 to $44.00 and set an “overweight” rating on the stock in a report on Tuesday, October 21st. Barclays started coverage on shares of Exelixis in a research report on Wednesday, September 17th. They issued an “equal weight” rating and a $40.00 price target on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 price objective on shares of Exelixis in a report on Tuesday, October 21st. Finally, Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.53.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.